ASH Selects 16 Fellows for Research Award to Support Careers in Academic Hematology
(WASHINGTON, October 2, 2018) – The American Society of Hematology (ASH) announced the names of 16 outstanding fellows selected to receive the 2018 ASH Research Training Award for Fellows (RTAF), a year-long program that aims to encourage careers in academic hematology by providing protected research time during training.
Each RTAF awardee will receive $70,000 to support a hematology research project throughout the program’s duration, from July 1, 2018, to June 30, 2019. The majority of the award money will support the recipient’s salary, with a percentage to be used for research supplies and travel to related scientific meetings, including the ASH annual meeting. Awards are targeted to two groups of researchers based on experience: a Junior Investigator award for second- and third-year fellows, and a Senior Investigator award for fourth- and fifth-year fellows.
The 2018 ASH Research Training Award for Fellows recipients and their research topics are:
| Recipients | Research Topics |
|
Theodora Anagnostou, MD College of Medicine, Mayo Clinic Rochester, MN |
Phenotypic characterization and activation of PD1-TIM3+ T-cells in follicular lymphoma |
|
Theodore Braun, MD, PhD Oregon Health and Science University Portland, OR |
Oncogene cooperativity in CSF3R-CEBPA co-mutated acute myeloid leukemia |
|
Pavel Davizon-Castillo, MD University of Colorado Denver Denver, CO |
Aging-associated platelet hyperreactivity and thrombosis |
|
Bhavya Doshi, MD Children's Hospital of Philadelphia Philadelphia, PA |
A longitudinal analysis of BAFF in the anti-factor VIII immune response |
|
James Godfrey, MD University of Chicago Chicago, IL |
Utilizing the T cell inflamed phenotype to identify molecular markers of response and resistance to PD-1 blockade in diffuse large B-cell lymphoma |
|
Kandace Gollomp, MD University of Pennsylvania Philadelphia, PA |
The role of neutrophils and NETs in the prothrombotic nature of heparin-induced thrombocytopenia |
|
Adam Greenbaum, MD, PhD University of Washington Seattle, WA |
Mechanisms of T-cell exhaustion in non-Hodgkin's lymphoma |
|
David Hsieh, MD University of Texas Southwestern Medical School Dallas, TX |
Precision medicine in AML: DCAF15 expression, RBM39 degradation, and spliceosome mutations as predictors of indisulam sensiti |
|
Adam Kittai, MD Oregon Health and Science University Portland, OR |
Phase I study of NEDD8 inhibitor pevonedistat in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma |
|
David Knorr, MD, PhD The Rockefeller University New York, NY |
Enhanced activity of anti-CD47 antibodies through Fc engineering |
|
Vidyasagar Koduri, MD, PhD Dana-Farber Cancer Institute Boston, MA |
A novel positive selection screen for destabilizers of IKZF1 in multiple myeloma |
|
Hojun Li, MD, PhD Dana-Farber Cancer Institute Boston, MA |
Deciding cell fate in hematopoiesis: asymmetric cell division in erythropoiesis as a model |
|
Reid Merryman, MD Dana-Farber Cancer Institute Boston, MA |
Tumor microenvironment and response to immune checkpoint therapy in follicular lymphoma |
|
Soo Park, MD University of California La Jolla, CA |
Impact of the aging epigenome on the pathogenesis of myelodysplastic syndrome |
|
Ami Patel, MD University of Utah Salt Lake City, UT |
Bone marrow stroma-based mechanisms of resistance in FLT3-ITD+ acute myeloid leukemia |
|
Pamela Sung, MD, PhD University of Pennsylvania Philadelphia, PA |
Understanding mechanisms of primary resistance to targeted therapy in FLT3-mutated acute myeloid leukemia |
The American Society of Hematology (ASH) (www.hematology.org)
is the world’s largest professional society of hematologists dedicated to
furthering the understanding, diagnosis, treatment, and prevention of disorders
affecting the blood. For more than 50 years, the Society has led the
development of hematology as a discipline by promoting research, patient care,
education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the
most cited peer-reviewed publication in the field, which is available weekly in
print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org),
an online, peer-reviewed open-access journal.
CONTACT:
Sara Khalaf, American Society of Hematology
[email protected]; 202-552-4925
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission